Marta Garcia-Forn

Marta Garcia-Forn

Auto-generated profile, based on publicly available information

Marta Garcia-Forn

Facultat de Medicina i Ciències de la Salut, Institut de Neurociències, Universitat de Barcelona, Barcelona, Catalonia, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2019 in Brain
Verified
Journal Article
Closed access
JCJordi Creus-Muncunill
Jordi Creus-Muncunill
RBRaquel Badillos-Rodríguez
Raquel Badillos-Rodríguez
MGMarta Garcia-Forn
Marta Garcia-Forn
MMMercè Masana
Mercè Masana
GBGerardo Garcia-Díaz Barriga
Gerardo Garcia-Díaz Barriga
EPEsther Pérez-Navarro
Esther Pérez-Navarro
See Brouillet and Merienne (doi:10.1093/brain/awz274) for a scientific commentary on this article.Creus-Muncunill et al. report that protein translation is altered in the striatum of Huntington’s disease mouse models, with upregulated expression of proteins from ribosomal and oxidative phosphorylation pathways. Pharmacological normalization of protein translation in R6/1 mice ameliorates motor disturbances and normalizes ribosomal content in the striatum.

28 December 2020 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
RVRafael Alcalá Vida
Rafael Alcalá Vida
MGMarta Garcia‐Forn
Marta Garcia‐Forn
CCCarla Castany‐Pladevall
Carla Castany‐Pladevall
JCJordi Creus‐Muncunill
Jordi Creus‐Muncunill
YIYoko Ito
Yoko Ito
EPEsther Perez-Navarro
Esther Perez-Navarro
Lamins are crucial proteins for nuclear functionality. Here, we provide new evidence showing that increased lamin B1 levels contribute to the pathophysiology of Huntington’s disease (HD), a CAG repeat‐associated neurodegenerative disorder. Through fluorescence‐activated nuclear suspension imaging, we show that nucleus from striatal medium‐sized spiny and CA1 hippocampal neurons display increased lamin B1 levels, in correlation with altered nuclear morphology and nucleocytoplasmic transport disruption. Moreover, ChIP‐sequencing analysis shows an alteration of lamin‐associated chromatin domains in hippocampal nuclei, accompanied by changes in chromatin accessibility and transcriptional dysregulation. Supporting lamin B1 alterations as a causal role in mutant huntingtin‐mediated neurodegeneration, pharmacological normalization of lamin B1 levels in the hippocampus of the R6/1 mouse model of HD by betulinic acid administration restored nuclear homeostasis and prevented motor and cognitive dysfunction. Collectively, our work points increased lamin B1 levels as a new pathogenic mechanism in HD and provides a novel target for its intervention.

1 December 2021 in Biological Psychiatry
Verified
Journal Article
Open access
ABAndrea Boitnott
Andrea Boitnott
MGMarta Garcia-Forn
Marta Garcia-Forn
DUDévina C. Ung
Dévina C. Ung
KNKristi Niblo
Kristi Niblo
DMDanielle Mendonca
Danielle Mendonca
SRSilvia De Rubeis
Silvia De Rubeis
Mutations in the X-linked gene DDX3X account for approximately 2% of intellectual disability in females, often comorbid with behavioral problems, motor deficits, and brain malformations. DDX3X encodes an RNA helicase with emerging functions in corticogenesis and synaptogenesis. We generated a Ddx3x haploinsufficient mouse (Ddx3x+/- females) with construct validity for DDX3X loss-of-function mutations. We used standardized batteries to assess developmental milestones and adult behaviors, as well as magnetic resonance imaging and immunostaining of cortical projection neurons to capture early postnatal changes in brain development. Ddx3x+/- females showed physical, sensory, and motor delays that evolved into behavioral anomalies in adulthood, including hyperactivity, anxiety-like behaviors, cognitive impairments in specific tasks (e.g., contextual fear memory but not novel object recognition memory), and motor deficits. Motor function declined with age but not if mice were previously exposed to behavioral training. Developmental and behavioral changes were associated with a reduction in brain volume, with some regions (e.g., cortex and amygdala) disproportionally affected. Cortical thinning was accompanied by defective cortical lamination, indicating that Ddx3x regulates the balance of glutamatergic neurons in the developing cortex. These data shed new light on the developmental mechanisms driving DDX3X syndrome and support construct and face validity of this novel preclinical mouse model.

18 November 2020 in Cells
Verified
Journal Article
Open access
PDF file
MGMarta Garcia-Forn
Marta Garcia-Forn
ABAndrea Boitnott
Andrea Boitnott
ZAZeynep Akpinar
Zeynep Akpinar
SRSilvia De Rubeis
Silvia De Rubeis
Autism spectrum disorder (ASD) is a prevalent neurodevelopmental disorder characterized by impairments in social communication and social interaction, and the presence of repetitive behaviors and/or restricted interests. In the past few years, large-scale whole-exome sequencing and genome-wide association studies have made enormous progress in our understanding of the genetic risk architecture of ASD. While showing a complex and heterogeneous landscape, these studies have led to the identification of genetic loci associated with ASD risk. The intersection of genetic and transcriptomic analyses have also begun to shed light on functional convergences between risk genes, with the mid-fetal development of the cerebral cortex emerging as a critical nexus for ASD. In this review, we provide a concise summary of the latest genetic discoveries on ASD. We then discuss the studies in postmortem tissues, stem cell models, and rodent models that implicate recently identified ASD risk genes in cortical development.

1 December 2018 in Neurobiology of Disease
Verified
Journal Article
Closed access
MGMarta García-Forn
Marta García-Forn
SMSara Martínez-Torres
Sara Martínez-Torres
GBGerardo García-Díaz Barriga
Gerardo García-Díaz Barriga
JAJordi Alberch
Jordi Alberch
MMMontse Milà
Montse Milà
EPEsther Perez-Navarro
Esther Perez-Navarro

27 December 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
LSLeticia Perez Sisques
Leticia Perez Sisques
JSJúlia Solana-Balaguer
Júlia Solana-Balaguer
Genís Campoy-CamposGenís Campoy-Campos
Genís Campoy-Campos
NMNúria Martín-Flores
Núria Martín-Flores
ASAnna Sancho-Balsells
Anna Sancho-Balsells
CMCristina Malagelada
Cristina Malagelada
RTP801/REDD1 is a stress-regulated protein whose levels are increased in several neurodegenerative diseases such as Parkinson’s, Alzheimer’s, and Huntington’s diseases (HD). RTP801 downregulation ameliorates behavioral abnormalities in several mouse models of these disorders. In HD, RTP801 mediates mutant huntingtin (mhtt) toxicity in in vitro models and its levels are increased in human iPSCs, human postmortem putamen samples, and in striatal synaptosomes from mouse models of the disease. Here, we investigated the role of RTP801 in the hippocampal pathophysiology of HD. We found that RTP801 levels are increased in the hippocampus of HD patients in correlation with gliosis markers. Although RTP801 expression is not altered in the hippocampus of the R6/1 mouse model of HD, neuronal RTP801 silencing in the dorsal hippocampus with shRNA containing AAV particles ameliorates cognitive alterations. This recovery is associated with a partial rescue of synaptic markers and with a reduction in inflammatory events, especially microgliosis. Altogether, our results indicate that RTP801 could be a marker of hippocampal neuroinflammation in HD patients and a promising therapeutic target of the disease.